Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Maurantonio

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Acta Diabetologica|December 7, 2018
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?Amedeo Lonardo, Simonetta Lugari, Stefano Ballestri, et al.
Current Pharmaceutical Design|February 12, 2013
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLDLucia Carulli, Mauro Maurantonio, Lionel Hebbard, et al.
Archives of Medical Research|August 17, 2011
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?Mauro Maurantonio, Stefano Ballestri, Maria Rosaria Odoardi, et al.
World Journal of Gastroenterology|November 1, 2017
Nonalcoholic fatty liver disease: Evolving paradigmsAmedeo Lonardo, Fabio Nascimbeni, Mauro Maurantonio, et al.
Diagnostics (Basel, Switzerland)|January 13, 2021
Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver DiseaseStefano Ballestri, Alessandro Mantovani, Enrica Baldelli, et al.
Internal and Emergency Medicine|March 13, 2026
Management of subjects with type 2 diabetes hospitalized in internal medicine units: a cluster-randomized, multicenter study before and after an educational programAntonio Ceriello, Andrea Fontanella, Tiziana Marcella Attardo, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Acta Diabetologica|December 7, 2018
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?Amedeo Lonardo, Simonetta Lugari, Stefano Ballestri, et al.
Current Pharmaceutical Design|February 12, 2013
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLDLucia Carulli, Mauro Maurantonio, Lionel Hebbard, et al.
Archives of Medical Research|August 17, 2011
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?Mauro Maurantonio, Stefano Ballestri, Maria Rosaria Odoardi, et al.
World Journal of Gastroenterology|November 1, 2017
Nonalcoholic fatty liver disease: Evolving paradigmsAmedeo Lonardo, Fabio Nascimbeni, Mauro Maurantonio, et al.
Diagnostics (Basel, Switzerland)|January 13, 2021
Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver DiseaseStefano Ballestri, Alessandro Mantovani, Enrica Baldelli, et al.
Internal and Emergency Medicine|March 13, 2026
Management of subjects with type 2 diabetes hospitalized in internal medicine units: a cluster-randomized, multicenter study before and after an educational programAntonio Ceriello, Andrea Fontanella, Tiziana Marcella Attardo, et al.
Pageof 1